Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003;20(1):1-5.
doi: 10.1385/MO:20:1:1.

Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience

V R Pai  1 , A T Mazumdar, C D Deshmukh, A V Bakshi, D M Parikh, P M Parikh, R C Mistry, K A Pathak
Affiliations
Clinical Trial

Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience

V R Pai et al. Med Oncol. 2003.

Abstract

Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerated, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck.

PubMed Disclaimer

References

    1. Oncol Rep. 1998 Sep-Oct;5(5):1251-3 - PubMed
    1. Oncol Rep. 1998 Nov-Dec;5(6):1499-505 - PubMed
    1. Semin Oncol. 1988 Feb;15(1):70-85 - PubMed
    1. Oncology. 1993 Mar-Apr;50(2):86-91 - PubMed
    1. Semin Oncol. 1988 Jun;15(3 Suppl 3):45-59 - PubMed

LinkOut - more resources